查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961191

小規模生物反應器市場－全球產業規模、佔有率、趨勢、機會和預測：按最終用戶、產品、地區和競爭對手分類，2021-2031年

Small-scale Bioreactors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By End user, By Product (Reusable Bioreactors, Single-use Bioreactors), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球小型生物反應器市場預計將從 2025 年的 16.4 億美元成長到 2031 年的 20.9 億美元，複合年成長率為 4.12%。

該領域涵蓋工作量較小的緊湊型培養系統，專為實驗室研究、製程開發和高通量篩檢應用而設計。主要成長要素包括對經濟高效的研究工作流程日益成長的需求，以及加速新型生物製藥商業化的迫切需求。隨著製藥公司專注於快速細胞株篩檢以縮短研發週期，對早期工具的投資顯著增加。根據歐洲製藥工業協會聯合會（EFPIA）的數據，預計到2024年，歐洲以研發為基礎的製藥業將在研發方面投入約550億歐元，這凸顯了支撐這些技術應用的雄厚資金支持。

市場概覽
預測期 2027-2031
市場規模：2025年 16.4億美元
市場規模：2031年 20.9億美元
複合年成長率：2026-2031年 4.12%
成長最快的細分市場 可重複使用的生物反應器
最大的市場 北美洲

儘管市場成長勢頭強勁，但在將實驗成果轉化為商業化生產方面仍面臨諸多挑戰。小型容器內複雜的流體動態和混合特性通常與工業儲槽截然不同，導致數據不一致，並使技術轉移變得複雜。這些技術限制要求製造商進行嚴格的檢驗研究，以確保在實驗室環境中確定的參數能夠在大規模生產環境中重現。此類要求可能會無意中延誤生產進度，並阻礙市場的順利擴張。

市場促進因素

生物製藥和生物相似藥研發管線的顯著成長是推動小規模生物反應器應用的主要動力。隨著產業轉向單株抗體和重組蛋白等多樣化治療方法，對高通量製程開發工具的需求日益成長，這些工具能夠在藥物研發早期階段實現實驗並行化並最佳化細胞培養條件。研發管線活動的增加需要穩健的小體積系統來篩檢克隆並在放大生產前確定關鍵程式參數。根據美國食品藥物管理局（FDA）於2025年1月發布的《2024年新藥核准年度報告》，該機構在2024年核准了50種新藥，這凸顯了大量需要進行廣泛上市前測試的新型分子。此外，正如BioSpace在2025年報告的那樣，2024年全球製藥研發支出將達到近2,880億美元，為實驗室採用先進的桌上型系統提供了必要的資金。

同時，對細胞和基因治療研究投入的增加正在改變小規模生物反應器市場。與生物製藥不同，細胞和基因療法的工作流程通常依賴規模化而非規模化策略，這使得小容量反應器對於患者特異性自體療法和病毒載體的生產至關重要。由於這些先進治療方法的複雜性，需要對小規模培養環境進行精確控制，以確保產品在整個臨床階段的安全性和一致性。該領域的經濟實力直接影響設備的採購。根據再生醫學聯盟於2025年1月發布的《產業趨勢簡報》，2024年細胞和基因治療領域的投資金額達152億美元，呈現顯著的年成長。這將支持為這些標靶治療引入專用生物反應器。

市場挑戰

全球小規模生物反應器市場面臨的一大障礙是難以將實驗室數據可靠地推廣到商業化生產。與大型工業槽相比，小型培養系統在流體動態、混合效率和剪切應力分佈等方面往往表現出截然不同的特性。這些物理差異導致針對小規模容器最佳化的生物過程在大體積下無法穩定運作。因此，製造商必須進行大量的檢驗研究，以確保小規模實驗結果的可推廣性，而這一過程削弱了最初推動這些技術應用的速度和效率優勢。

製程轉移可能性的不確定性為製藥研發公司帶來了巨大的財務風險，也使得它們在關鍵生產決策中不敢完全依賴小規模系統。當資料無法無縫外推時，企業將面臨研發週期延長和後期失敗的風險。根據歐洲製藥工業協會聯合會（EFPIA）預測，到2024年，新型化學品或生物製藥的研發成本預計將達到約31.3億歐元。鑑於如此巨大的資本風險，缺乏可保證的規模化生產能力迫使相關人員繼續進行重疊的中試規模操作，最終限制了小規模生物反應器的整體市場滲透率。

市場趨勢

人工智慧 (AI) 與數位雙胞胎的融合正在變革小規模生物反應器的應用，將製程開發從純粹的經驗迭代轉向預測建模。透過將桌上型反應器與In Silico模擬結合，並模擬各種培養條件，開發人員有效地減少了定義設計空間所需的物理實驗數量。這種數位化分層有效地彌合了研發與商業化生產之間的技術鴻溝，使操作人員能夠利用來自小型運行的即時數據來最佳化補料策略並預測放大後的性能。正如羅克韋爾自動化公司 2025 年 6 月發布的《智慧製造報告：生命科學版》所指出的，目前有 35% 的生命科學製造商正在考慮使用數位雙胞胎技術和模擬工具來提升營運決策和預測能力。

同時，細胞和基因療法研發的日益普及，對高度依賴小型系統的分散式生產能力提出了迫切需求。隨著產業朝向自體移植和個人化醫療方向發展，傳統的集中式供應鏈模式已無法滿足需求，亟需能夠在分散式和床邊環境中可靠運作的小規模生物反應器。先進治療方法的需求與現有基礎設施之間的這種不匹配，正成為硬體創新的重要催化劑，促使供應商開發具有更高物流柔軟性的系統。根據Cytiva於2025年10月發布的《全球生物製藥韌性指數》，超過25%的生物製藥高層表示，目前的供應鏈無法有效支持細胞和基因療法等先進治療方法，凸顯了市場對高度適應性小規模生產技術的迫切需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：小規模生物反應器的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按最終用戶分類（製藥和生物製藥公司、合約研究組織和合約生產組織、學術和研究機構）
    • 產品類別（可重複使用生物反應器（不鏽鋼生物反應器、玻璃生物反應器）、一次性生物反應器）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美小規模生物反應器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲小規模生物反應器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區小規模生物反應器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲小規模生物反應器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲小規模生物反應器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球小規模生物反應器市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corp.
  • Lonza Group Ltd.
  • Eppendorf SE
  • Miltenyi Biotec India Pvt Ltd.
  • Getinge AB
  • Solaris Biotech USA, Inc.
  • Infors AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24005

The Global Small-scale Bioreactors Market is projected to expand from a valuation of USD 1.64 Billion in 2025 to USD 2.09 Billion by 2031, reflecting a CAGR of 4.12%. This sector encompasses compact culture systems with reduced working volumes, specifically engineered for laboratory research, process development, and high-throughput screening applications. Key growth drivers include the rising demand for cost-effective research workflows and the urgent need to expedite the commercialization of new biologics. As pharmaceutical firms focus on rapid cell line screening to shorten development cycles, investment in early-stage tools has risen markedly. Data from the European Federation of Pharmaceutical Industries and Associations indicates that in 2024, the research-based pharmaceutical industry in Europe invested approximately 55,000 million euros in R&D, highlighting the significant financial backing supporting the adoption of these technologies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.64 Billion
Market Size 2031USD 2.09 Billion
CAGR 2026-20314.12%
Fastest Growing SegmentReusable Bioreactors
Largest MarketNorth America

Despite this strong growth trajectory, the market encounters a major obstacle related to scaling experimental results to commercial production. The intricate fluid dynamics and mixing properties within small vessels often vary fundamentally from those in industrial tanks, resulting in data discrepancies that complicate technology transfer. This technical constraint necessitates that manufacturers conduct rigorous validation studies to ensure that parameters defined in laboratory settings can be replicated in large-scale manufacturing environments. Such requirements can inadvertently delay production schedules and hinder seamless market expansion.

Market Driver

The substantial growth of the biopharmaceutical and biosimilars pipeline acts as a major driver for the adoption of small-scale bioreactors. With the industry pivoting toward diverse therapeutic modalities such as monoclonal antibodies and recombinant proteins, there is a heightened requirement for high-throughput process development tools capable of parallelizing experiments and optimizing cell culture conditions early in the drug development lifecycle. This increase in pipeline activity demands robust small-volume systems to screen clones and establish critical process parameters prior to scaling up. According to the FDA's '2024 New Drug Therapy Approvals Annual Report' released in January 2025, the agency approved 50 novel drugs in 2024, underscoring the significant volume of new molecules requiring extensive pre-commercial testing. Additionally, BioSpace reported in 2025 that global pharmaceutical R&D spending hit nearly $288 billion in 2024, providing the necessary capital for laboratories to procure advanced benchtop systems.

Simultaneously, escalating investment in cell and gene therapy research is transforming the small-scale bioreactor market. Unlike conventional biologics, cell and gene therapy workflows frequently rely on scale-out strategies rather than scale-up, rendering small-volume vessels essential for manufacturing patient-specific autologous therapies and viral vectors. The intricate nature of these advanced therapies necessitates precise control over culture environments at smaller scales to guarantee product safety and consistency throughout clinical phases. This sector's financial strength directly influences equipment purchasing; the Alliance for Regenerative Medicine's 'State of the Industry Briefing' from January 2025 noted that investment in the cell and gene therapy sector reached $15.2 billion in 2024, a significant annual increase that supports the deployment of specialized bioreactors for these targeted treatments.

Market Challenge

A critical barrier facing the Global Small-scale Bioreactors Market is the difficulty in reliably scaling experimental data from laboratory environments to commercial production. Compact culture systems frequently demonstrate fluid dynamics, mixing efficiencies, and shear stress profiles that differ fundamentally from those found in large-scale industrial tanks. These physical discrepancies generate a disconnect wherein biological processes that are optimized in small vessels do not perform consistently when scaled to higher volumes. As a result, manufacturers must perform extensive validation studies to confirm that findings from small-scale experiments are transferable, a process that undermines the speed and efficiency benefits that initially prompt the adoption of these technologies.

This uncertainty regarding process transferability introduces significant financial risk for pharmaceutical developers, making them hesitant to rely exclusively on small-scale systems for critical manufacturing decisions. When data cannot be seamlessly extrapolated, companies encounter extended development timelines and the possibility of late-stage failures. According to the European Federation of Pharmaceutical Industries and Associations, the estimated cost to research and develop a new chemical or biological entity was approximately 3,130 million euros in 2024. Given this substantial capital exposure, the lack of guaranteed scalability compels stakeholders to sustain redundant pilot-scale operations, thereby limiting the overall market penetration of small-scale bioreactors.

Market Trends

The integration of Artificial Intelligence and Digital Twins is transforming the application of small-scale bioreactors by moving process development from purely empirical iteration to predictive modeling. Developers are increasingly combining benchtop vessels with in silico replicas to simulate various culture conditions, effectively reducing the number of physical experiments needed to define design spaces. This digital layering enables operators to optimize feeding strategies and forecast scale-up performance using real-time data from small-volume runs, successfully bridging the technical divide between R&D and commercial manufacturing. As noted in Rockwell Automation's 'State of Smart Manufacturing Report: Life Sciences Edition' from June 2025, 35% of life sciences manufacturers are currently exploring digital twin technologies and simulation tools to improve their operational decision-making and predictive abilities.

Concurrently, the rising utilization of cell and gene therapy development is creating a critical demand for decentralized manufacturing capabilities heavily reliant on compact systems. As the industry progresses toward autologous and personalized treatments, traditional centralized supply chain models are becoming insufficient, necessitating small-scale bioreactors capable of reliable operation in distributed or bedside settings. This mismatch between advanced therapeutic requirements and existing infrastructure serves as a major catalyst for hardware innovation, driving vendors to create systems with enhanced logistical flexibility. According to Cytiva's 'Global Biopharma Resilience Index' published in October 2025, over 25% of biopharma executives indicated that their current supply chains cannot effectively support advanced modalities like cell and gene therapies, highlighting the urgent market need for adaptable small-scale production technologies.

Key Market Players

  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corp.
  • Lonza Group Ltd.
  • Eppendorf SE
  • Miltenyi Biotec India Pvt Ltd.
  • Getinge AB
  • Solaris Biotech USA, Inc.
  • Infors AG

Report Scope

In this report, the Global Small-scale Bioreactors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Small-scale Bioreactors Market, By End user

  • Pharmaceutical & Biopharmaceutical Companies
  • CROs & CMOs
  • Academic & Research Institutes

Small-scale Bioreactors Market, By Product

  • Reusable Bioreactors( Stainless Steel Bioreactors, Glass Bioreactors)
  • Single-use Bioreactors

Small-scale Bioreactors Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Small-scale Bioreactors Market.

Available Customizations:

Global Small-scale Bioreactors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Small-scale Bioreactors Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By End user (Pharmaceutical & Biopharmaceutical Companies, CROs & CMOs, Academic & Research Institutes)
    • 5.2.2. By Product (Reusable Bioreactors( Stainless Steel Bioreactors, Glass Bioreactors), Single-use Bioreactors)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Small-scale Bioreactors Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By End user
    • 6.2.2. By Product
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Small-scale Bioreactors Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By End user
        • 6.3.1.2.2. By Product
    • 6.3.2. Canada Small-scale Bioreactors Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By End user
        • 6.3.2.2.2. By Product
    • 6.3.3. Mexico Small-scale Bioreactors Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By End user
        • 6.3.3.2.2. By Product

7. Europe Small-scale Bioreactors Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By End user
    • 7.2.2. By Product
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Small-scale Bioreactors Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By End user
        • 7.3.1.2.2. By Product
    • 7.3.2. France Small-scale Bioreactors Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By End user
        • 7.3.2.2.2. By Product
    • 7.3.3. United Kingdom Small-scale Bioreactors Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By End user
        • 7.3.3.2.2. By Product
    • 7.3.4. Italy Small-scale Bioreactors Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By End user
        • 7.3.4.2.2. By Product
    • 7.3.5. Spain Small-scale Bioreactors Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By End user
        • 7.3.5.2.2. By Product

8. Asia Pacific Small-scale Bioreactors Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By End user
    • 8.2.2. By Product
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Small-scale Bioreactors Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By End user
        • 8.3.1.2.2. By Product
    • 8.3.2. India Small-scale Bioreactors Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By End user
        • 8.3.2.2.2. By Product
    • 8.3.3. Japan Small-scale Bioreactors Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By End user
        • 8.3.3.2.2. By Product
    • 8.3.4. South Korea Small-scale Bioreactors Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By End user
        • 8.3.4.2.2. By Product
    • 8.3.5. Australia Small-scale Bioreactors Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By End user
        • 8.3.5.2.2. By Product

9. Middle East & Africa Small-scale Bioreactors Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By End user
    • 9.2.2. By Product
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Small-scale Bioreactors Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By End user
        • 9.3.1.2.2. By Product
    • 9.3.2. UAE Small-scale Bioreactors Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By End user
        • 9.3.2.2.2. By Product
    • 9.3.3. South Africa Small-scale Bioreactors Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By End user
        • 9.3.3.2.2. By Product

10. South America Small-scale Bioreactors Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By End user
    • 10.2.2. By Product
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Small-scale Bioreactors Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By End user
        • 10.3.1.2.2. By Product
    • 10.3.2. Colombia Small-scale Bioreactors Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By End user
        • 10.3.2.2.2. By Product
    • 10.3.3. Argentina Small-scale Bioreactors Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By End user
        • 10.3.3.2.2. By Product

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Small-scale Bioreactors Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Sartorius AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific Inc.
  • 15.3. Merck KGaA
  • 15.4. Danaher Corp.
  • 15.5. Lonza Group Ltd.
  • 15.6. Eppendorf SE
  • 15.7. Miltenyi Biotec India Pvt Ltd.
  • 15.8. Getinge AB
  • 15.9. Solaris Biotech USA, Inc.
  • 15.10. Infors AG

16. Strategic Recommendations

17. About Us & Disclaimer